Capricor Therapeutics Inc. (NASDAQ:CAPR) shares are trending on Friday.
Shares of the clinical-stage biotechnology company climbed 67.22% to $7.04 after the bell on Thursday.
In the regular session, CAPR closed at $4.21, up 0.48%, according to Benzinga Pro data.
The stock saw elevated trading activity, with volume reaching 16.75 million shares, about 3.6 times its average daily volume of 4.64 million shares. CAPR’s short interest stands at 30.5%.
Earnings, Regulatory Update Behind The Move
On Thursday after the market closed, Capricor announced second-quarter results for the period ended Jun. 30.
The company posted no revenue for the quarter, as it did not recognize any revenue in the first half of 2026 or 2025.
Capricor reported a quarterly loss of $0.70 per share, missing the analyst estimate of a $0.58 per-share loss by 20.7%.
As of Jun. 30, cash, cash equivalents and marketable securities totaled approximately $237.9 million, down from $318.1 million as of Dec. 31, 2025.
The company stated that it believes that, based on its current operating plan and financial resources, its available cash, cash equivalents and marketable securities are sufficient to fund its operating capital requirements for at least the next twelve months.
FDA Review, CEO Commentary
The company said its Deramiocel Biologics License Application remains under active Food and Drug Administration review, with an update expected shortly.
CEO Linda Marban said, “We are continuing to work with the Agency on a path forward.”
Trading Metrics, Technical Analysis
Capricor has a market capitalization of approximately $243.81 million. Its stock has traded between a 52-week high of $40.37 and a 52-week low of $2.96.
CAPR has a Relative Strength Index (RSI) of 16.47.
Over the past 12 months, the small-cap biotech stock has fallen 45.89%.
Currently, CAPR is trading close to its 52-week low.
Benzinga’s Edge Stock Rankings indicates CAPR stock has a negative price trend across all time frames.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Pavel Kapysh from Shutterstock
Login to comment